menu
    • menu

    Company profile for InteRNA Technologies

    NEW Drugs in Dev: 1
    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.

    Virtual Booth

    Contact Supplier

    Munit offers scalable GMP micronization and particle size engineering to enhance drug solubility, bioavailability, and performance.

    Virtual Booth

    Contact Supplier

    pharmacompass-1-m-2026-04-20

    Virtual Booth

    Contact Supplier

    PMC Isochem is your partner for smart CDMOs of Intermediates, APIs, & excipients & a catalog of Intermediates & Generic APIs.

    Virtual Booth

    Contact Supplier

    Expand your portfolio with Egis- value-added generics, API capabilities, and reliable contract services to drive your growth.

    Virtual Booth

    Contact Supplier

    pharmacompass-2-m-2026-04-20

    Virtual Booth

    Contact Supplier

    EVENTS

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass

    Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

    Update your Virtual Booth on PharmaCompass, ask us

    About

    InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. Using its leading microRNA (miRNA) discovery and functional validation platform, InteRNA is developing a pipeline of proprietary preclinical miRNA drug candidates targeting key processes in cancer initiation and progression. Enabled with a 3rd generation drug delivery formulation, these miRNA compounds can ...
    InteRNA is a Dutch biotechnology company specializing in the development of RNA therapeutics for the treatment of cancer. Using its leading microRNA (miRNA) discovery and functional validation platform, InteRNA is developing a pipeline of proprietary preclinical miRNA drug candidates targeting key processes in cancer initiation and progression. Enabled with a 3rd generation drug delivery formulation, these miRNA compounds can mount a coordinated anti-cancer attack by engaging multiple signal transduction targets simultaneously. With this approach, we address the high need for novel therapeutics with improved efficacy.

    List your booth number for exhibitions, ask us

    CONTACT DETAILS

    Click the arrow to open the dropdown
    Contact SupplierContact
    Google MapGoogle Map
    Full View ScreenFull View Screen
    InteRNA TechnologiesNetherlands1 Flag
    Country
    Country
    Netherlands
    Address
    Address
    Nijmegen City Centre Jonkerbosplein 52 6534 AB Nijmegen
    Telephone
    Telephone
    +31 24 352 96 33
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://interna-technologies.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/interna-technologies-bv/?originalSubdomain=nl
    youtube
    YouTube
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Events

    Webinars & Exhibitions

    Request a meetingRequest a meeting
    Full Screen ViewFull Screen View
    AMWC Asia-TDAC

    AMWC Asia-TDAC

    Not Confirmed

    envelop Contact Supplier

    AMWC Asia-TDAC

    Post an Enquiry

    Meeting

    Digital content

    Create Content with PharmaCompass, ask us

    NEWS #PharmaBuzz

    read-more
    read-more
    FDA approves InteRNA Technologies’ Phase I solid tumour treatment study
    FDA approves InteRNA Technologies’ Phase I solid tumour treatment study

    03 Dec 2021

    // CLINICALTRIALSARENA

    https://www.clinicaltrialsarena.com/news/fda-interna-phase-i-solid-tumour/

    CLINICALTRIALSARENA
    03 Dec 2021
    Share Share
    FDA Clears InteRNA's IND for Phase I Trial of INT-1B3 in Advanced Solid Tumors
    FDA Clears InteRNA's IND for Phase I Trial of INT-1B3 in Advanced Solid Tumors

    02 Dec 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211202005045/en

    BUSINESSWIRE
    02 Dec 2021
    Share Share
    InteRNA Technologies Establishes Clinical Advisory Board, Appoints New Members
    InteRNA Technologies Establishes Clinical Advisory Board, Appoints New Members

    19 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211019005517/en

    BUSINESSWIRE
    19 Oct 2021
    Share Share
    InteRNA Appoints Andrea van Elsas to its Supervisory Board
    InteRNA Appoints Andrea van Elsas to its Supervisory Board

    12 Oct 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20211012005116/en

    BUSINESSWIRE
    12 Oct 2021
    Share Share
    InteRNA Publishes Preclinical Data from Investigational microRNA INT-1B3
    InteRNA Publishes Preclinical Data from Investigational microRNA INT-1B3

    24 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210324005075/en/InteRNA-Technologies-Publishes-Preclinical-Data-from-Investigational-microRNA-INT-1B3-Program-in-Molecular-Therapy-%E2%80%93-Nucleic-Acids-and-Oncotarget

    BUSINESSWIRE
    24 Mar 2021
    Share Share
    InteRNA Publishes Preclinical Data from Investigational microRNA INT-1B3
    InteRNA Publishes Preclinical Data from Investigational microRNA INT-1B3

    23 Mar 2021

    // BUSINESSWIRE

    https://www.businesswire.com/news/home/20210324005075/en

    BUSINESSWIRE
    23 Mar 2021
    Share Share

    ABOUT THIS PAGE

    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    • Privacy policy
    • Terms and conditions
    • Disclaimers
    • LinkedIn
    • Product listings are provided for informational purposes only. We do not supply or sell any products. Any products that may be covered by patent(s) are supplied solely for uses permitted under Section 107A of the Indian Patents Act and not for commercial sale.

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search